To examine the role of extracorporeal membrane oxygenation (ECMO) as potential therapeutic option for severe cases of acute respiratory distress syndrome (ARDS).
INTRODUCTION
In recent years, the use of extracorporeal membrane oxygenation (ECMO) to treat acute respiratory failure has dramatically increased even if evidence of benefit on mortality from large randomized clinical trials is still lacking [1] . Paden et al. [2 && ] showed that in the United States from 1996 to 2006 the use of ECMO stably remained around 100 cases a year, but in 2009 it increased dramatically up to 400 patients per year. Factors that may explain this increase in the use of ECMO are the H1N1 pandemic influenza [1] ; the publication of the results of a recent randomized clinical trial [3] ; and the technological development of ECMO devices [4, 5] .
During the H1N1 pandemic, hundreds of acute respiratory distress syndrome (ARDS) patients worldwide received ECMO. The Australian and New Zealand network reported 68 patients with suspected H1N1-associated ARDS treated with ECMO with 71% survival to ICU discharge [6] . The Italian ECMO network reported 60 patients with a survival of 77% in patients receiving ECMO within 7 days from the onset of mechanical ventilation [7] . Conventionally, patients with ARDS need ECMO for a short-term respiratory or respiratory circulatory-associated support as a therapeutic option that may restore oxygenation when 'conventional' supportive therapy fails. A more extended use would indicate ECMO as a total or partial alternative to mechanical ventilation to minimize ventilator-induced lung injury (VILI).
In the present article, we will describe the basic technological and physiological principles of ECMO; discuss the current 'conventional' indication as supportive therapy for hypoxemia refractory to standard treatments; and examine the possible 'nonconventional' use of ECMO as partial or total alternative to mechanical ventilation.
WHAT IS EXTRACORPOREAL MEMBRANE OXYGENATION?
The basic characteristics of extracorporeal devices are described in details elsewhere [8] [9] [10] . ECMO devices conventionally used in patients with ARDS require vascular catheters with high diameter and wire-reinforced thin walls to minimize flow resistances and reduce the incidence of kinking. The modern oxygenators are made with polymethylpentene fibers that present low resistance, lesser incidence of thrombocytopenia and lower consumption of blood products and are connected to an oxygen source. These new devices are capable of oxygen delivery (3 ml/kg/min) and CO 2 removal (3-6 ml/kg/min) equal to the normal metabolism of the patient [5] . In general with ECMO, blood flow and FiO 2 are the main determinant of arterial oxygenation, whereas CO 2 elimination depends on sweep gas flow through the oxygenator. Other factors that influence oxygen transfer are bloodoxygen saturation in the ECMO drainage cannula, hemoglobin concentration and intrinsic membrane-oxygenator properties, which depend on exchange-membrane surface and O 2 diffusibility through hollow microfibers. In this case, total support devices are able to completely supply the physiological blood gas exchanges normally performed by the native lungs. Blood should be reinfused in the aorta (in case of arterial-venous bypass) or in the right atrium (for veno-venous bypass) to obtain respectively cardiac and respiratory or only lung function support. It is also necessary to use high heparin doses and elevated volumes of priming for the device for proper function. A ratio between ECMO flow and cardiac output more than 60% can be constantly associated with adequate blood oxygenation, oxygen transport and delivery [11] . The ECMO device can be 'undersized' to remove CO 2 (partial extracorporeal support: ECCO 2 -R). The ability to remove CO 2 correlates with the level of blood flow level, the characteristics of membrane lung, the sweep gas rate and the patient's basal carbon dioxide production [5, 12, 13] . ECCO 2 -R may be considered as an intermediate level of technical complexity. Small (14-Fr), usually doublelumen catheters allow a blood flow of 0.3-0.5 l/min, which is constantly guaranteed by a roller nonocclusive pump designed to minimize hemolysis. Blood is driven through an oxygenator membrane, which is connected to an oxygen source of 6-8 l/min. Some devices also include a hemofilter in series with the oxygenator, to allow the extraction of plasmatic water that is reinfused in the circuit, in order to lower hematocrit and to prevent blood clotting. A centrifugal pump, which creates a radial flow going through an annular fiber oxygenator, has also been used in other veno-venous ECCO 2 -R systems. This design maximizes the exchange surface, and therefore, the device efficiency. Both technological implementations are able to remove up to 25% of carbon dioxide production and can transfer no more than 10 ml/min of oxygen. Low doses of heparin (4-18 IU/min) are necessary to avoid clotting occurrence [12] .
During the extracorporeal procedures, complications may arise from malfunction of the device or from patient-related adversities. Technical complications occur in 5% of treated patients and are represented by pump and cannula malfunction. Regarding patient-related complications, the most frequent is bleeding, which occurs with a frequency of up to 30%, hematological changes during extracorporeal support such as hemolysis, coagulation problems with clotting in the circuit and thrombocytopenia due to heparin use or to blood surface exposure.
Extracorporeal membrane oxygenation as rescue therapy of acute respiratory distress syndrome
ARDS is characterized by heterogeneous lung damage with significant variations in severity, and
KEY POINTS
In the last decade, vast technical improvements in technology have made ECMO practice much simpler, less invasive, more biocompatible, inherently safer and relatively cheaper.
The advances in technology and clinical practice, especially after the H1N1 pandemic influenza experience, have convinced clinicians to extend ECMO support to other fields such as severe bridge to lung transplant, COPD, ARDS combined with intracranial bleeding, asthma and also to facilitate the use of 'ultra-protective' mechanical ventilation in severe ARDS (employing V T <6 ml/kg PBW and lowering airway pressures) minimizing the risk of VILI.
To date, a standardized selection criteria for patients who will benefit from ECMO therapy does not yet exist, a future trial aimed to test a defined protocol with clear patient selection criteria and no cross-over treatments would clarify the validity of ECMO support in ARDS patients.
consequently in survival. Mortality from severe ARDS in the 1970s was as high as 85-90%, but from 2000, it decreased to 20-40% [14] . Refractory hypoxemia, that is PaO 2 less than 60 mmHg for at least 1 h while receiving an FIO 2 of 1.0 is rare and a nonfrequent cause of death (15% of ARDS deaths). The use of ECMO to treat refractory hypoxemia was controversial for the last 40 years. In the past, the highly specialized equipment and knowledge required to provide ECMO made this technique available only in a few medical centers. In the last decade, vast improvements in technology have made ECMO simpler, less invasive, more biocompatible, inherently safer and relatively cheaper (Figs 1 and 2) [15, 16] .
All these technological advances increased the practice of inter-hospital transfer of patients requiring ECMO: recent reports suggest that the transfer of patients with severe hypoxia to specialized centers is becoming a standard practice.
The Conventional ventilation of Ecmo for Severe Adult Respiratory failure (CESAR) trial is the only published study in the last two decades that evaluated modern ECMO practice. The CESAR study shows that an ECMO-based management protocol significantly improves survival without severe disability, if compared with conventional mechanical ventilation. The absolute risk reduction for the primary outcome (death or severe disability) was 16%, which translates to a number needed to treat of six patients [17] . Major biases of the study are represented by inter-site variations of mechanical ventilation strategy (the condition of patients in the conventional arm did not get a standardized ventilatory treatment) and the 'center experience' led to an improved outcome in patients randomized in the ECMO arm.
Referral networks of selected ICUs able to provide advanced respiratory care for patients with ARDS, up to ECMO, started with the emergency of H1N1 influenza [8] . In the Italian ECMO network experience, clinicians planned two complementary strategies to minimize risks associated with patient transport: indication to move patients toward specialized centers based on a risk anticipation principle: clinical criteria for the transfer were chosen to allow the mobilization in advance of the largest possible proportion of patients potentially at risk of severe respiratory deterioration; identification of precise criteria to place the patients under the responsibility of expert teams, able to place ECMO and then provide safe transportation FIGURE 1. The use of ECMO to treat refractory hypoxemia. Patient on V-V ECMO (a) for PGF and severe-associated ARDS, following one-lung transplantation. PGF represents a severe form of ischemia-reperfusion lung injury to the lung allograft occurring in the early posttransplant period characterized by diffuse alveolar opacities (developing within 72 h of transplantation) and an arterial partial pressure of oxygen/fraction of inspired oxygen (PaO 2 /FIO 2 ) ratio of less than 100 (beyond 48 h postoperatively) [15] . A different value of compliance between the right (transplanted) and the left (native) lung needed ILV with two different ventilatory strategies: HFOV (b) in the transplanted lung to recruit the lung and protective low volume ventilation (c) in the native lung [16] . ARDS, acute respiratory distress syndrome; HFOV, high-frequency oscillatory ventilation; ILV, independent lung ventilation; PGF, primary graft failure.
to the patients with ECMO toward the referral center. In 2011, Noah et al. [18] compared in a cohort of 80 patients with severe H1N1-related ARDS the hospital mortality of patients referred, accepted and transferred for ECMO with matched patients who were not referred for ECMO in the United Kingdom during the H1N1 pandemic in winter 2009-2010. The hospital mortality rate was 23.7% for ECMO-referred patients vs. 52.5% for non-ECMO-referred patients. A subsequent study from the French Research Network identified new factors associated with survival in ECMO patients (age, lactate and plateau pressure). The authors analyzed the factors associated with in-ICU death in ECMO recipients and the potential benefit of ECMO using a propensity score-matched (1 : 1) cohort analysis. Mortality was not different between the two matched cohorts, but authors signaled that 51 ECMO patients who could not be matched were younger, had lower PaO 2 /FIO 2 ratio, had higher plateau pressure, but also had a lower ICU mortality rate, than the 52 matched ECMO patients (22 vs. 50%) [19] .
A special warning should be raised for the patients with severe ARDS caused by sepsis or septic shock with a higher cardiac output and impaired peripheral oxygen extraction. In these situations, even ECMO flow up to 6 l/min might not achieve adequate blood oxygenation and O 2 delivery particularly if the pulmonary gas-exchange capacity is severely impaired. When blood oxygenation and SaO 2 and O 2 delivery remain low despite maximal ECMO flow, clinicians should consider increasing the threshold of blood transfusion to a value of hemoglobin of 10 g/dl.
EXTRACORPOREAL MEMBRANE OXYGENATION TO PREVENT VENTILATOR-INDUCED LUNG INJURY
Mechanical ventilation is a lifesaving treatment delivered in various settings. The thought of artificially inflating the lung with air has been considered and mentioned since the ancient Egyptians and in the Bible, as nicely described by Baker [20] in his 'Artificial respiration, the history of an idea'. Interestingly, the article that provided the first formal description of mechanical ventilation as a clinical tool anticipated the possibility of replacing the function of the lung by extracorporeal means by trying 'whether the suffering the Blood to circulate through a vessel, so as it may be openly exposed to the fresh Air, will not suffice for the life of an animal' [21] . V T of 6 ml/kg predicted body weight (PBW) and end-inspiratory plateau pressure (P PLAT ) of a maximum of 30 cm H 2 O represent the gold standard of mechanical ventilation in ARDS patients [14] . However, it is still unclear whether tidal volume as low as 6 ml/kg and plateau pressures less than 30 cmH 2 O are safe enough or an additional reduction of these thresholds would further reduce VILI and improve the survival rate. Along this line of research, Terragni et al. [22] demonstrated with computed tomography scan of the chest that about one-third of patients with severe ARDS, although ventilated with tidal volumes of 6 ml/kg of PBW, had evidence of alveolar overdistension. Accordingly, Hager et al. [23] showed that a plateau pressure of 30 cmH 2 O in some patients may not be safe and suggested that the lower the plateau pressure the lower the mortality rate. This further reduction in VT and Pplat may theoretically be managed by two different kinds of extracorporeal support: extracorporeal CO 2 removal (ECCO 2 -R or partial ECMO support) [4, 5] ; total ECMO support in which the clinician can select the right ventilatory setting increasing the blood flow from two liters (to remove total CO 2 ) to 5-6 l in cases of severe hypoxemia [7] [8] [9] [10] .
The use of ECMO to 'rest the lung' was first tested by Gattinoni et al. [24] who showed that FIGURE 2. Radiographic feature of primary graft failure in severe ARDS patient following one-lung transplantation. A case of independent high-frequency oscillatory ventilation in the management of asymmetric ARDS: right transplanted (T) and the left native lung (N). ILV is often applied in asymmetric lung injury because application of tidal inflation and PEEP to the heterogeneous lung may overdistend the uninvolved lung and divert pulmonary blood flow to the injured lung area, thus worsening ventilation/perfusion mismatch [16] . ARDS, acute respiratory distress syndrome; ILV, independent lung ventilation; PEEP, positive endexpiratory pressure.
ECMO was associated to an observed mortality rate of 51%, significantly lower than that predicted in these patients. Unfortunately, the study did not have a control group. Moreover, the authors reported a significant incidence of adverse effects, such as blood loss in the circuit, need for blood transfusion (1800 ml per day) and bleeding from the insertion site of the catheters of the extracorporeal circuit. Morris et al. [25] published a randomized clinical trial comparing pressure controlled inverse-ratio ventilation with an extracorporeal CO 2 removal technique in patients with ARDS. However, no significant difference in survival was found between the mechanically ventilated patients and those treated with the extracorporeal CO 2 removal strategy.
More recently, a pumpless extracorporeal technique (interventional Lung Assist: iLA NovaLung GmbH, Hechingen, Germany) has been proposed for the treatment of patients with critical hypoxia/ hypercapnia [26] . A membrane with high efficiency in CO 2 removal is placed in an artero-venous extracorporeal circuit (usually between the femoral artery and the femoral vein). Blood flow is driven by the artero-venous pressure gradient through a very low-resistance heparin coated circuit, and therefore, it cannot be controlled, but depends only on the hemodynamic features of the patient. Moreover, similarly to the ECMO technique, the arterial cannulation can induce lower limb ischemia if the use of this device is required for a prolonged period of time. These limitations may reduce the clinical indication for this very promising strategy. The efficacy of a new minimally invasive CO 2 removal technique using an extracorporeal membrane gas exchanger placed into a veno-venous pump-driven bypass has been evaluated in severe ARDS patients [27] . The main features of this system are a lower blood flow (191-422 ml/min -5-10% of cardiac output), a small neonatal membrane lung (0.33 m 2 ) instead of two large adult membrane lungs (3-4.5 m 2 each), the use of smaller (14-French) double-lumen catheters and a relatively small infusion rate of heparin (3-19 IU/kg). This minimally invasive CO 2 removal technique efficiently and safely contributed to the correction of the respiratory acidosis consequent to the significant reduction of tidal volume in individuals with severe ARDS, allowing a more protective ventilation strategy.
A recent trial from Bein et al. [28 & ] demonstrated the efficacy of ventilation with very low tidal volume (<3 ml/kg PBW) combined with a pumpless arterial-venous extracorporeal technique device in improving clinical outcome in ARDS patients with a PaO 2 /FIO 2 less than 150. This trial confirms the feasibility and the potential efficacy of a 'super protective' ventilatory strategy that combines very low tidal volume with extracorporeal elimination of carbon dioxide as previously reported by Terragni et al. [12] .
CONCLUSION
Successful clinical trials with statistical significance are difficult to perform in intensive care patient populations. Involving highly specialized treatments, studies on critical care lack clear definitions and classification of their critical clinical conditions. Identification of patients with more severe respiratory diseases could be crucial to evaluate the treatment in more homogeneous populations. For this reason, a revised definition of clinical criteria for ARDS, the 'Berlin definition', was recently established to classify patients according to their disease severity [29,30 && ]. ARDS was classified depending on oxygenation as mild, moderate or severe if PaO 2 /FiO 2 was, respectively, between 201 and 300 mmHg, 101 and 200 mm Hg or 100 mm Hg or less, using a minimal positive end-expiratory pressure level of 5 cm H 2 O. Oxygenation criteria were well correlated to severity, with a mortality corresponding to 27, 32 and 45% in mild, moderate and severe ARDS. These new P/F thresholds chosen for the different levels of ARDS severity could be helpful in categorizing patients with respect to different therapeutic approaches identifying a P/F ratio less than 100 mm as main entry criteria for trials testing ECMO in severe ARDS [29] .
The EOLIA trial (ECMO to rescue Lung Injury in severe ARDS; ClinicalTrials.gov NCT01470703) and the SUPERNOVA trial (A Strategy of UltraProtective lung ventilation with Extracorporeal CO 2 Removal for New-Onset moderate to seVere ARDS; ESICM trial group-registration on going) have been designed according to these principles. The former will evaluate the impact of ECMO, instituted early after the diagnosis of ARDS not evolving favorably after 3-6 h under optimal ventilatory management and maximum medical treatment, on the morbidity and mortality associated with this disease, the latter will evaluate whether a strategy of enhanced lung-protective (lower tidal volume and lower pressure) ventilation, along with control of the ensuing hypercapnia using the latest generation ECCO 2 R devices, will improve clinical outcomes compared with standard-of-care lung-protective ventilation in patients with moderate ARDS.
